News & views
Our collective understanding of mental health is increasing all the time, with advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.
For media inquiries, contact us at media@compasspathways.com

September 06, 2023
COMPASS Pathways announces publication of first study evaluating potential of AI model to predict outcomes of COMP360 psilocybin treatment in treatment-resistant depression

August 16, 2023
COMPASS Pathways Announces Up to $285 Million Private Placement Financing Joined by Leading Healthcare Investors

August 03, 2023
COMPASS Pathways Announces Second Quarter 2023 Financial Results and Business Highlights

July 25, 2023
First clinical study results of psilocybin treatment in anorexia nervosa published in Nature Medicine

July 17, 2023
COMPASS Pathways announces publication of positive data from treatment-resistant depression phase 2 clinical trial of COMP360 psilocybin alongside antidepressants in Nature journal, Neuropsychopharmacology

July 13, 2023
Opinion paper calls for clarity on the definition of “psychedelic-assisted therapy” using psilocybin

July 06, 2023
American Medical Association Releases Language of First New Current Procedural Terminology Code for Psychedelic Therapies

July 05, 2023
COMPASS Pathways Secures Term Loan Facility for Up to $50 Million from Hercules Capital
Looking for older news & views posts? View COMPASS news archive